Inactivated trivalent influenza vaccine
Inactivated trivalent influenza vaccine is a biological therapy with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult
Influenza Vaccine To Prevent Adverse Vascular Events:Pilot
Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)
A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants
Clinical Trials (7)
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult
Influenza Vaccine To Prevent Adverse Vascular Events:Pilot
Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)
A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants
Direct and Indirect Protection by Influenza Vaccine Given to Children in India
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
All 7 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 7